Annual CFO
-$5.88 M
-$1.00 M-20.53%
31 August 2023
Summary:
Lexaria Bioscience annual cash flow from operations is currently -$5.88 million, with the most recent change of -$1.00 million (-20.53%) on 31 August 2023. During the last 3 years, it has fallen by -$1.89 million (-47.41%). LEXX annual CFO is now -1932.15% below its all-time high of $321.00 thousand, reached on 31 October 2013.LEXX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.27 M
-$646.50 K-104.34%
31 May 2024
Summary:
Lexaria Bioscience quarterly cash flow from operations is currently -$1.27 million, with the most recent change of -$646.50 thousand (-104.34%) on 31 May 2024. Over the past year, it has increased by +$355.60 thousand (+21.93%). LEXX quarterly CFO is now -532.26% below its all-time high of $292.90 thousand, reached on 31 October 2011.LEXX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$4.69 M
+$519.90 K+9.98%
31 May 2024
Summary:
Lexaria Bioscience TTM cash flow from operations is currently -$4.69 million, with the most recent change of +$519.90 thousand (+9.98%) on 31 May 2024. Over the past year, it has increased by +$1.19 million (+20.27%). LEXX TTM CFO is now -1141.10% below its all-time high of $450.40 thousand, reached on 31 July 2013.LEXX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LEXX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +21.9% | +20.3% |
| 3 y3 years | -47.4% | -13.8% | -17.5% |
| 5 y5 years | -95.7% | -71.9% | -56.0% |
LEXX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -47.4% | at low | -104.3% | +29.1% | -17.5% | +20.3% |
| 5 y | 5 years | -124.6% | at low | -128.1% | +29.1% | -79.1% | +20.3% |
| alltime | all time | -1932.2% | at low | -532.3% | +29.1% | -1141.1% | +20.3% |
Lexaria Bioscience Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| May 2024 | - | -$1.27 M(+104.3%) | -$4.69 M(-10.0%) |
| Feb 2024 | - | -$619.60 K(-47.6%) | -$5.21 M(-10.5%) |
| Nov 2023 | - | -$1.18 M(-27.1%) | -$5.82 M(-1.1%) |
| Aug 2023 | -$5.88 M(+20.5%) | -$1.62 M(-9.2%) | -$5.88 M(+8.2%) |
| May 2023 | - | -$1.79 M(+45.4%) | -$5.44 M(+10.7%) |
| Feb 2023 | - | -$1.23 M(-1.4%) | -$4.91 M(-1.0%) |
| Nov 2022 | - | -$1.25 M(+5.8%) | -$4.96 M(+1.6%) |
| Aug 2022 | -$4.88 M(+22.3%) | -$1.18 M(-6.6%) | -$4.88 M(+1.3%) |
| May 2022 | - | -$1.26 M(-1.4%) | -$4.81 M(+2.2%) |
| Feb 2022 | - | -$1.28 M(+9.5%) | -$4.71 M(+8.4%) |
| Nov 2021 | - | -$1.17 M(+4.9%) | -$4.35 M(+8.9%) |
| Aug 2021 | -$3.99 M(+52.3%) | -$1.11 M(-3.8%) | -$3.99 M(+13.4%) |
| May 2021 | - | -$1.16 M(+26.9%) | -$3.52 M(+16.0%) |
| Feb 2021 | - | -$911.20 K(+12.6%) | -$3.03 M(+5.5%) |
| Nov 2020 | - | -$809.50 K(+26.6%) | -$2.87 M(+9.7%) |
| Aug 2020 | -$2.62 M(-12.9%) | -$639.30 K(-4.7%) | -$2.62 M(-3.6%) |
| May 2020 | - | -$670.50 K(-11.1%) | -$2.72 M(-13.7%) |
| Feb 2020 | - | -$753.90 K(+35.8%) | -$3.15 M(+5.0%) |
| Nov 2019 | - | -$555.10 K(-24.6%) | -$3.00 M(-0.3%) |
| Aug 2019 | -$3.01 M(+19.4%) | -$736.60 K(-33.1%) | -$3.01 M(-3.2%) |
| May 2019 | - | -$1.10 M(+82.6%) | -$3.11 M(+21.1%) |
| Feb 2019 | - | -$603.30 K(+6.9%) | -$2.56 M(+0.1%) |
| Nov 2018 | - | -$564.30 K(-32.6%) | -$2.56 M(+1.7%) |
| Aug 2018 | -$2.52 M(+62.9%) | -$837.10 K(+49.6%) | -$2.52 M(+23.8%) |
| May 2018 | - | -$559.70 K(-6.9%) | -$2.03 M(-2.1%) |
| Feb 2018 | - | -$600.90 K(+15.5%) | -$2.08 M(+5.7%) |
| Nov 2017 | - | -$520.30 K(+47.3%) | -$1.97 M(+27.1%) |
| Aug 2017 | -$1.55 M(+133.9%) | -$353.30 K(-41.5%) | -$1.55 M(+6.4%) |
| May 2017 | - | -$603.50 K(+23.6%) | -$1.45 M(+51.7%) |
| Feb 2017 | - | -$488.10 K(+383.3%) | -$958.20 K(+73.3%) |
| Nov 2016 | - | -$101.00 K(-61.3%) | -$552.90 K(-16.3%) |
| Aug 2016 | -$660.90 K(-56.0%) | -$260.80 K(+140.8%) | -$660.80 K(-32.6%) |
| May 2016 | - | -$108.30 K(+30.8%) | -$980.90 K(-22.1%) |
| Feb 2016 | - | -$82.80 K(-60.4%) | -$1.26 M(-18.1%) |
| Nov 2015 | - | -$208.90 K(-64.0%) | -$1.54 M(+2.4%) |
| Aug 2015 | -$1.50 M | -$580.90 K(+50.5%) | -$1.50 M(+31.3%) |
| May 2015 | - | -$386.10 K(+7.0%) | -$1.14 M(+33.9%) |
| Feb 2015 | - | -$360.90 K(+108.4%) | -$853.90 K(+73.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2014 | - | -$173.20 K(-22.3%) | -$493.00 K(+46.1%) |
| Aug 2014 | -$515.80 K(-260.7%) | - | - |
| July 2014 | - | -$222.90 K(+130.0%) | -$337.40 K(+522.5%) |
| Apr 2014 | - | -$96.90 K(+5.4%) | -$54.20 K(-132.5%) |
| Jan 2014 | - | -$91.90 K(-223.7%) | $166.70 K(-48.1%) |
| Oct 2013 | $321.00 K(+136.2%) | $74.30 K(+23.2%) | $321.10 K(-28.7%) |
| July 2013 | - | $60.30 K(-51.4%) | $450.40 K(+2.9%) |
| Apr 2013 | - | $124.00 K(+98.4%) | $437.90 K(+79.5%) |
| Jan 2013 | - | $62.50 K(-69.3%) | $244.00 K(+79.4%) |
| Oct 2012 | $135.90 K(+23.8%) | $203.60 K(+325.9%) | $136.00 K(-39.6%) |
| July 2012 | - | $47.80 K(-168.4%) | $225.30 K(+50.8%) |
| Apr 2012 | - | -$69.90 K(+53.6%) | $149.40 K(+10.3%) |
| Jan 2012 | - | -$45.50 K(-115.5%) | $135.50 K(+23.3%) |
| Oct 2011 | $109.80 K(-133.2%) | $292.90 K(-1142.3%) | $109.90 K(-130.9%) |
| July 2011 | - | -$28.10 K(-66.5%) | -$356.20 K(+13.8%) |
| Apr 2011 | - | -$83.80 K(+17.9%) | -$313.00 K(-6.2%) |
| Jan 2011 | - | -$71.10 K(-58.9%) | -$333.80 K(+1.0%) |
| Oct 2010 | -$330.30 K(+807.4%) | -$173.20 K(-1247.0%) | -$330.40 K(-2020.9%) |
| July 2010 | - | $15.10 K(-114.4%) | $17.20 K(-137.2%) |
| Apr 2010 | - | -$104.60 K(+54.5%) | -$46.20 K(+17.3%) |
| Jan 2010 | - | -$67.70 K(-138.8%) | -$39.40 K(+8.2%) |
| Oct 2009 | -$36.40 K(-225.5%) | $174.40 K(-461.1%) | -$36.40 K(-87.5%) |
| July 2009 | - | -$48.30 K(-50.6%) | -$290.10 K(+115.0%) |
| Apr 2009 | - | -$97.80 K(+51.2%) | -$134.90 K(+152.1%) |
| Jan 2009 | - | -$64.70 K(-18.4%) | -$53.50 K(-284.5%) |
| Oct 2008 | $29.00 K(-113.3%) | -$79.30 K(-174.2%) | $29.00 K(-10.5%) |
| July 2008 | - | $106.90 K(-751.8%) | $32.40 K(-118.4%) |
| Apr 2008 | - | -$16.40 K(-192.1%) | -$175.70 K(-0.5%) |
| Jan 2008 | - | $17.80 K(-123.5%) | -$176.60 K(-19.2%) |
| Oct 2007 | -$218.60 K(+42.5%) | -$75.90 K(-25.0%) | -$218.50 K(-1.8%) |
| July 2007 | - | -$101.20 K(+485.0%) | -$222.60 K(+29.9%) |
| Apr 2007 | - | -$17.30 K(-28.2%) | -$171.40 K(-2.6%) |
| Jan 2007 | - | -$24.10 K(-69.9%) | -$175.90 K(+14.7%) |
| Oct 2006 | -$153.40 K(+262.6%) | -$80.00 K(+60.0%) | -$153.40 K(+109.0%) |
| July 2006 | - | -$50.00 K(+129.4%) | -$73.40 K(+213.7%) |
| Apr 2006 | - | -$21.80 K(+1262.5%) | -$23.40 K(+1362.5%) |
| Jan 2006 | - | -$1600.00 | -$1600.00 |
| Oct 2005 | -$42.30 K | - | - |
FAQ
- What is Lexaria Bioscience annual cash flow from operations?
- What is the all time high annual CFO for Lexaria Bioscience?
- What is Lexaria Bioscience quarterly cash flow from operations?
- What is the all time high quarterly CFO for Lexaria Bioscience?
- What is Lexaria Bioscience quarterly CFO year-on-year change?
- What is Lexaria Bioscience TTM cash flow from operations?
- What is the all time high TTM CFO for Lexaria Bioscience?
- What is Lexaria Bioscience TTM CFO year-on-year change?
What is Lexaria Bioscience annual cash flow from operations?
The current annual CFO of LEXX is -$5.88 M
What is the all time high annual CFO for Lexaria Bioscience?
Lexaria Bioscience all-time high annual cash flow from operations is $321.00 K
What is Lexaria Bioscience quarterly cash flow from operations?
The current quarterly CFO of LEXX is -$1.27 M
What is the all time high quarterly CFO for Lexaria Bioscience?
Lexaria Bioscience all-time high quarterly cash flow from operations is $292.90 K
What is Lexaria Bioscience quarterly CFO year-on-year change?
Over the past year, LEXX quarterly cash flow from operations has changed by +$355.60 K (+21.93%)
What is Lexaria Bioscience TTM cash flow from operations?
The current TTM CFO of LEXX is -$4.69 M
What is the all time high TTM CFO for Lexaria Bioscience?
Lexaria Bioscience all-time high TTM cash flow from operations is $450.40 K
What is Lexaria Bioscience TTM CFO year-on-year change?
Over the past year, LEXX TTM cash flow from operations has changed by +$1.19 M (+20.27%)